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Abstract
Androgen deprivation therapy remains the primary treatment modality for patients with metastatic prostate cancer
but is uniformly marked by progression to castration-resistant prostate cancer (CRPC) after a period of regression.
Continued activation of androgen receptor (AR) signaling is attributed as one of the most important mechanisms
underlying failure of therapy. Recently, the discovery of constitutively active AR splice variants (AR-Vs) adds more
credence to this idea. Expression of AR-Vs in metastases portends a rapid progression of the tumor. However, the
precise role of the AR-Vs in CRPC still remains unknown. ARv567es is one of the two AR variants frequently found in
human CRPC xenografts and metastases. Herein, we developed a probasin (Pb) promoter–driven ARv567es trans-
genic mouse, Pb-ARv567es, to evaluate the role of ARv567es in both autonomous prostate growth and progression to
CRPC. We found that expression of ARv567es in the prostate results in epithelial hyperplasia by 16 weeks and
invasive adenocarcinoma is evident by 1 year of age. The underlying genetic cellular events involved a cell
cycle–related transcriptome and differential expression of a spectrum of genes that are critical for tumor initiation
and progression. These findings indicate that ARv567es could induce tumorigenesis de novo and signifies the
critical role of AR-Vs in CRPC. Thus, the Pb-ARv567es mouse could provide a novel model in which the role of
AR variants in prostate cancer progression can be examined.
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Introduction
Patients with castration-resistant prostate cancer (CRPC) have an
average survival time of 16 to 18 months from identification of
recurrence [1–3]. Despite intensive investigation, treatment resis-
tance of CRPC remains a significant clinical challenge, as the under-
lying mechanisms are still not fully understood. Persistence of
intratumoral androgens [3–6], activation of alternate signaling path-
ways that could enhance androgen receptor (AR) activity in the pres-
ence of lower levels of androgen [7–11], and overexpression of AR
that could promote sensitivity to low levels of ligand are all proposed
mechanisms for the development of CRPC. Recently, the discovery
of constitutively active AR splice variants (AR-Vs) adds credence to
the idea that continued signaling through the AR plays a strong role
in the development of CRPC [12–15].
The AR-Vs have different structures with each lacking portions of
the ligand-binding domain [16–21]. Functionally, these truncated
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AR variants are constitutively active, ligand-independent tran-
scription factors that can support androgen-independent expression
of AR target genes. The potential role of AR-Vs in driving prostate
cancer progression is supported by several independent clinical cor-
relation studies [17,18,22] and provides a conceptually simple expla-
nation for the development of resistance to prostate cancer therapies
that target the ligand-binding domain. However, the mechanisms by
which the splice variants could mediate progression of prostate cancer
following castration still need to be elucidated.
ARv567es, in which exons 5, 6, and 7 are deleted, is one of the
two AR variants frequently found in human CRPC xenografts and
human metastases [12,20,22,23]. Expression in metastases portends
a rapid progression of the tumor [22]. Currently, the limited studies
on ARv567es are confined to expression testing with xenografts and
functional exploration in in vitro cell lines [12,20,22,23]. The pre-
cise role of the ARv567es in normal prostate growth and CRPC
is unknown.
Materials and Methods
Generation of a Transgenic Mouse Model Expressing Human
AR Variant, ARv567es, in Prostate Epithelium
Mice were bred and housed under specific pathogen-free condi-
tions in the University of Washington animal facility in accordance
with institutional guidelines. To create the Pb-ARv567es transgenic
(Tg) mouse used in this study, we replaced the SV40T fragment
from the AAR2PB-SV40T expression cassette [24] with the cDNA
fragment encoding ARv567es. The construction of cDNA encoding
ARv567es has been previously described [20,24]. The entire rPB-
ARv567es expression cassette was gel isolated following digestion with
SpeI and was microinjected into fertilized C57BL/6 embryos (per-
formed at the University of Washington Comparative Medicine
Transgenic Core Facility).
Genotyping
Tg progeny were identified by polymerase chain reaction (PCR)
analysis of DNA extracted from tail biopsies of 3-week-old mice. Tail
tips were lysed (25 mM NaOH and 2 mM EDTA) and boiled for
30 minutes; after cooling, the mixture was placed in neutralization
buffer (40 mM Trizma base). Integration of a single intact ARv567es
transgene copy was confirmed by genomic PCR with limited tem-
plate dilution using AccuPrime Taq high fidelity DNA polymerase
(Life Technologies, Grand Island, NY), a forward primer specific for
rabbit β-globin intron (5′-CCGGGCCCCTCTGCTAACCA-3′),
and a reverse primer specific for ARv567es (5′-TCCTCGTCCG-
GAGGTGCTGG-3′).
Castration Studies
Castration studies were performed on 16-week-old mice and 49-
to 52-week-old mice. Pb-ARv567es and wild-type (Wt) littermates
were either castrated or had sham surgery performed. Mice were sac-
rificed 3 weeks post-surgery. At the time of sacrifice, the prostate and
genitourinary (GU) organs as well as liver, lung, and kidneys were
harvested and weighed. Half of the prostate was then placed in for-
malin and other half in RNAlater. All other organs collected were
placed only in formalin.
Polymerase Chain Reaction
Total RNA was obtained from prostates using TRIzol (Life Tech-
nologies). RNA was converted to cDNA using SuperScript First-
Strand Synthesis System according to the manufacturer’s protocol
with random primers (Life Technologies). Relative quantitative reverse
transcription-PCR (qRT-PCR) was then performed using a ViiA 7
Real-Time PCR system (Life Technologies) and iTaq Universal SYBR
Green Supermix (Bio-Rad Laboratories, Hercules, CA). PCR data were
analyzed using ViiA 7 Software (Life Technologies). Target mRNA
levels were normalized against Rpi13a levels. ΔΔCT method was used
to compare the relative expression, and relative quantification (RQ)
value was achieved. The distribution of RQ of individuals in the Tg
and Wt groups was displayed as mean ± 1 SEM. TaqMan probe was
designed to target the unique ARv567es exon 4 and exon 8 junction:
6FAM-CCTTGCCTGATTGCGAGA-MGBNFQ. The following
primer pairs were used:
Immunohistochemistry
Prostates were fixed with formalin and then paraffin embedded.
Ten-micrometer-thick sections were made for hematoxylin and eosin
(H&E) staining as well as immunohistochemistry (IHC). We used
the Elite Vectastain ABC kits for IHC (Vector Laboratories, Inc,
Burlingame, CA). For better antigen retrieval, slides were placed in a
0.01 M citrate buffer for 25 minutes and then blocked with 5% serum
in phosphate-buffered saline (PBS). For mouse antibodies, we used an
additional blocking step (avidin blocking solution followed by a biotin
blocking solution; Vector Laboratories, Inc). When staining for non-
nuclear proteins, hematoxylin was used as a counterstain. Primary and
secondary antibodies were diluted in 5% serum/PBS. The human-
specific AR N-terminal antibody AR441 (Santa Cruz Biotechnology,
Santa Cruz, CA) and the murine-specific C-terminal antibody
EP670Y (Epitomics, Burlingame, CA) were used for detecting ARv567es
or endogenous mouse AR, respectively. Other primary antibodies
used were Ki-67 (Thermo Scientific, Fremont, CA), Ube2c (Boston
Biochem, Cambridge, MA), FoxA1, Twist, Vimentin (Abcam,
Cambridge, MA), and E-cadherin (BD Biosciences, San Jose, CA).
ARv567es Forward: CCT TGC TCT CTA GCC TCA ATG AA
Reverse: CTT GAT TAG CAG GTC AAA AGT GAA CT
Murine E2 ubiquitin-conjugating
enzyme (Ube2c)
Forward: GGT GAC AAA GGA ATC TCC GCC
Reverse: GGG AGA GTT TGT ACC TCA GGT
Nkx3.1 Forward: GGG CAC CAG TAA CAA TGG AG
Reverse: GGC AAA TGG CTT CTT TCT GT
Fkbp5 Forward: GGG CAC CAG TAA CAA TGG AG
Reverse: GGC AAA TGG CTT CTT TCT GT
Rpl13a Forward: CTG TGA AGG CAT CAA CAT TTC TG
Reverse: GAC CAC CAT CCG CTT TTT CTT
Kras Forward: TTT GGT GCA TGC AGT TGA TT
Reverse: GTG ACC CCT CAG TGT CCA GT
Fgfbp1 Forward: CTG CAT TCC CCA GTA CAC CT
Reverse: CTG AGA ACG CCT GAG TAG CC
Nfkb1 Forward: CTG ACC TGA GCC TTC TGG AC
Reverse: GCA GGC TAT TGC TCA TCA CA
Ccl2 Forward: AGG TCC CTG TCA TGC TTC TG
Reverse: TCT GGA CCC ATT CCT TCT TG
β-Catenin Forward: CTG CTC ATC CCA CTA ATG TC
Reverse: CTT TAT TAA CTA CCA CCT GGT CCT
Wnt11 Forward: GCC ATG AAG GCC TGC CGT AG
Reverse: GAT GGT GTG ACT GAT GGT GG
Lbp Forward: ACT TCT GAC CTG CAG CCT TA
Reverse: GAG CGG TGA TTC CGA TTA AA
Chodl Forward: CAG TGG AAT GAC GAC AGG TG
Reverse: GGT TCC CAA AGC AAC CAG TA
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DNA Fragmentation Terminal Deoxynucleotidyl Transferase–
Mediated dUTP Nick End Labeling Assay
The presence of apoptosis was determined by terminal deoxy-
nucleotidyl transferase–mediated dUTP nick end labeling (TUNEL),
using the DEADEND Colorimetric Apoptosis Detection System
(Promega,Madison,WI) as per themanufacturer’s instructions. Briefly,
paraffin-embedded slides were fixed in 4% paraformaldehyde in PBS
for 15 minutes after pretreatment. After washes, tissues were per-
meabilized in proteinase K for 30 minutes and then labeled in TdT
reaction mix for 60 minutes at 37°C. Reaction was stopped by im-
mersion in 2× saline-sodium citrate buffer (SCC) for 15 minutes,
and then streptavidin-HRP was added for 30 minutes followed by
DAB stain and hematoxylin counterstain.
Statistical Analyses
Weight data are displayed as mean ± 1 SD. Real-time PCR data
are displayed as mean ± 1 SEM. When two groups were compared,
two-tailed Student’s t test was used (GraphPad Prism, version 5.0d;
GraphPad Software, La Jolla, CA). A P value of .05 or less was
considered significant.
Results
To evaluate the role of the constitutively active AR splice variant
ARv567es in the autonomous state, we developed a probasin (Pb)
promoter–driven ARv567es Tg mouse, Pb-ARv567es. We targeted the
ARv567es coding sequence to the prostate epithelium of C57BL/6mouse
under the drive of the minimal rat Pb promoter (−426 to +28 bp) [24],
which we designated as the Pb-ARv567es mouse. Integration of a single
intact ARv567es transgene copy was confirmed by genomic PCR with
limited template dilution (Figure W1). Real-time RT-PCR using a
TaqMan probe targeted to the exon 4/8 junction of the variant dem-
onstrated the profuse presence of ARv567es transcripts in Pb-ARv567es
mice compared to Wt littermates (Figure 1A). Protein expression of
ARv567es in the prostate epithelium was further confirmed by immuno-
histochemistry staining with the human-specific AR N-terminal
antibody AR441, which was not detected in the Wt littermates
(Figure 1B) and no antibody control (Figure W3A). ARv567es protein
expression was detected in all four prostate lobes with a tendency of
higher expression in lateral and ventral lobes.
To investigate whether ARv567es functions in normal prostate
growth, and whether androgen could affect its function, we performed
castration and sham surgery on Pb-ARv567es and Wt mice at 16 weeks
of age. Three weeks post-surgery, the prostate and GU organs were
harvested and weighed. As shown in Figure 1, C and D, and
Table W1 in both the castrated and sham Pb-ARv567es mice, the pros-
tate and GU organs showed significantly higher relative weights
compared with those of Wt littermates (P < .05). Accordingly, the
proliferation rate of Pb-ARv567es mouse prostate increased with a
Figure 1. Ectopic expression of ARv567es in mouse prostate and augmentation of prostate growth. (A) qPCR with TaqMan probe targeted
to the junction of human AR exon 4 and exon 8 showed the expression levels of ARv567es in the Tg model. (B) Human AR splice variant
ARv567es expression was detected in four prostatic lobes of the Tg model but not in Wt mice. Antibody used was AR441, which reacts to
the human AR N terminus but not to mouse AR. Constitutively active ARv567es augmented prostate growth as shown by significantly
increased relative GU weight (C) and prostate weight (D) either in intact or castrated Tg mice. Relative weight is organ weight normalized
by body weight. (E) Significantly higher proliferation index in Pb-ARv567es prostate indicated by Ki-67 staining and positive cell count.
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Figure 2. ARv567es induced prostatic hyperplasia, PIN, and adenocarcinoma (×400). (A) Foci hyperplasia lesions (arrows) were evident in
Pb-ARv567es mice at 16 to 20 weeks of age, demonstrated by increased numbers of cells with normal or enlarged size in hyperprolifer-
ated epithelium. Comparatively normal prostatic epithelium could be seen in adjacent gland (arrowheads) showing normal single layer
structure. (B) PIN in Pb-ARv567es mice at 30 to 40 weeks of age (arrows) showed overlapping of cells, elongation of nuclei, and prom-
inence of nucleoli. (C) Prostate histology in old mice, 50 to 60 weeks. Wt group demonstrated normal-looking prostate with single layer
of glandular epithelium, normal nuclear and nuclear-to-cytoplasm ratio and low proliferation, and amorphic secretions containing numer-
ous atrophic epithelia. Castrated Wt mice showed atrophic cells and epithelium but retained organized structure. Pb-ARv567es mice
showed low-grade PIN in anterior prostate (AP) and dorsal prostate (DP) and high-grade PIN in lateral prostate (LP) and ventral prostate
(VP), which are shown as overlapping of epithelial cells forming multiple layer of epithelium, enlargement of nuclei and high nuclear-to-
cytoplasm ratio, and hyperchromatic nuclei with prominent nucleoli. Ventral prostate showed more advanced progression to well-
differentiated adenocarcinoma, which is shown as cellular changes corresponding to dysplasia, increased quantity of small glands,
and lymphocyte infiltration in stroma. Castrated Pb-ARv567es mice showed typical well-differentiated adenocarcinoma appearance,
which is shown as increased quantity of small glands, thickened stroma with infiltrated tumor cells, and round, dysplastic, and hyper-
chromatic nuclei with very little cytoplasm. Lymphocyte infiltration is very common.
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significantly higher Ki-67 index compared with Wt littermates (P <
.05) (Figures 1E and W3B). These data show that while ARv567es does
not maintain the normal differentiated growth of the prostate, ARv567es
does increase the proliferative rate of the prostate epithelium as seen
by the increased weight of the GU tract and prostate post-castration
in Pb-ARv567es versus Wt mice. The effect of ARv567es on apoptosis
was also determined by TUNEL assay (Figure W3C ). Comparable
appearances of apoptotic cells in Tg mice and Wt littermates indicated
an insignificant role of ARv567es on apoptosis protection.
Using qPCR and immunohistochemistry staining, we confirmed
the continued expression and nuclear localization of ARv567es after
castration (Figure W2, A and B), which signified the constitutive
activity of ARv567es in the absence of ligand binding. We also exam-
ined the endogenous mouse AR levels by IHC using a mouse-specific
C-terminal antibody, EP670Y, and showed that the expression of
mouse AR was significantly decreased after castration with only hints
of staining in the cytoplasm (Figures W2C ).
To further characterize the features of the Pb-ARv567es mouse, the
prostate histology was serially evaluated from 16 weeks of age up to
1 year (Table W2). Consistent with the prostate weight outcomes,
foci of hyperplasia could be seen in young adults (16 weeks; Fig-
ure 2A), with a gradual progression to prostatic intraepithelial neoplasia
(PIN) lesions by 40 weeks (Figure 2B). To investigate differences be-
tween intact and castrate mouse histology in older Pb-ARv567es mice,
castration and sham operations were also performed on 50-week-old
mice. Prostate histology was examined 3 weeks post-castration. Well-
differentiated adenocarcinoma could be seen in the sham-operatedmice
(Figure 2C ), which was characterized as increased quantity of small
Figure 3. Invasive adenocarcinoma in the ventral prostate of Pb-ARv567es mice. (A and B) Low power (×100) showing well-differentiated
adenocarcinoma in ventral prostates. Widespread and essentially diffuse PIN containing glands mixed with small glands (arrowheads)
and tumor cell infiltrations (*) in the surrounding fibromuscular stroma or looser connective tissue with desmoplastic response. (C and
D) Intermediate power (×200) showing unequivocal invasive small acinar adenocarcinoma, extensively extending into stroma and
periprostatic loose connective tissue (arrowheads). (E) Focus on a gland with complete epithelial cells infiltrating into surrounding
periprostatic connective tissue (*) and also forming small acini (arrowheads). (F) High power (×400) showing a distinct sheet of tumor
cell invasion into stroma (arrow) and a typical well-differentiated gland formed (arrowhead). (G–I) High magnification (×400). Immuno-
histochemistry of epithelial cell marker FoxA1 showing unequivocal invasive small acinar adenocarcinoma (arrowheads), extensively
extending into stoma and surrounding periprostatic loose connective tissue. In addition to invasion into stroma and periprostatic tissue,
overgrowing of epithelium causes cell shedding into the lumen (*). (G) A cluster of tumor cells appearing in the blood vessel (arrow)
signifying the possibility of metastasis through the bloodstream. (J) FoxA1 staining in age-matched Wt littermate (arrowhead). IHC with
AR441 antibody showed the expression of ARv567es in glands (K) and stroma (L) in the invasive tumor.
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glands, stromal thickening with desmoplastic response, hyperchromatic
round nuclei with increased mitosis, and frequent inflammation.
More advanced progression to invasive adenocarcinoma is evident in
the castrated group (Figure 3, A–F ), which displayed a ventral pros-
tate preference. The characterization of invasive adenocarcinoma
includes pronounced extension of smaller, well-formed acini into
surrounding stroma and periprostatic loose connective tissue with
significant desmoplastic response and inflammation [25].
To characterize the invasive adenocarcinoma, we performed IHC
against FOXA1 as well as epithelial to mesenchymal transition
(EMT) markers. FOXA1 staining confirmed epithelial tumor cell
infiltration into the periprostatic stroma and connective tissues where
they formed acini glands (Figure 3, G–I ). In one view (Figure 3G ),
tumor clumps can be seen in an interstitial blood vessel, which may
signify the possibility of metastasis through the blood stream. AR441
staining (Figure 3, K and L) showed constitutive expression of
variant ARv567es in the invasive tumor area. EMT markers were also
examined. Loss of E-cadherin and higher expression of Twist and
Vimentin (Figure 4A) strongly suggested that an EMT was one of
the most important mechanisms underlying ARv567es-induced inva-
sive phenotype development [26–28]. Except randomly localized
hyperplasia, none of the Wt littermates showed PIN or adeno-
carcinoma in all the age groups (Table W2). These data strongly
indicated that ARv567es can induce prostate cancer to develop in a
de novo way, and it has the potential to enhance the progression of
androgen-dependent disease to CRPC.
Recently, Hu et al. [29] characterized the distinct expression pat-
terns of gene sets induced by AR full length (AR-FL) and AR-Vs and
found that AR-Vs induced a top gene set enriched with cell cycle
genes, compared with the biosynthesis, metabolism, and secretion
Figure 4. Cellular reprogramming underlying the tumorigenesis of Pb-ARv567es prostate. (A) Differential expression of EMT markers in Wt
and Tg mice, including E-cadherin, Twist, and Vimentin, showed EMT contributing to ARv567es-induced tumorigenesis (×400). (B) IHC
staining in the aged mice (50-60 weeks) showed higher Ube2c expression in Pb-ARv567es prostate (×400). (C) qRT-PCR showed the RQ
of Ube2c mRNA levels in Tg Pb-ARv567es prostate and in Wt mice. qRT-PCR also showed increases in Fkbp5, a canonical AR-regulated
gene, Ki-67, and Nkx3.1.
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Figure 5. Mouse whole genome expression oligonucleotide microarray analyses showing the differentially regulated transcriptome in
Pb-ARv567es prostate. (A) Oncology-related gene categories that were significantly downregulated in Pb-ARV567es mice by microarray
GSEA (false discovery rate < 25%). (B) Oncology signatures significantly upregulated in Pb-ARV567es mice by microarray GSEA (false
discovery rate < 25%). (C) qPCR verification of SINGH_KRAS_DEPENDENCY_SIGNATURE up-regulation by showing higher expression
of Kras and Fgfbp1. (D) qPCR verification of HINATA_NFKB_IMMU_INF signature up-regulation by showing higher expression of Nfkb1
and Ccl2. (E) qPCR verification of HINATA_NFKB_IMMU_INF signature up-regulation including β-catenin gene, Wnt11, Lbp, and Chodl.
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gene sets induced by AR-FL [29]. Of the cell cycle genes increased by
AR-Vs, Ube2c is the most outstanding and its expression is signifi-
cantly correlated with AR-Vs but not AR-FL [29]. To investigate
whether ARv567es could also induce a similar transcriptome in the
Pb-ARv567es Tg mouse, we ran real-time PCR on prostates from
intact and castrated Pb-ARv567es mice; Tg prostates from castrated
mice showed increased expression of mitotic genes similar to those
seen in CRPC patients, including Ube2c (Figure 4C ). Upregulated
Ube2c protein levels were further confirmed by immunohisto-
chemistry compared with Wt control (Figure 4B). Other genes of
interest that were upregulated included the canonical AR-regulated
gene Fkbp5, the Nkx3.1 homeobox gene, and the proliferation
marker Ki-67 (Figure 4C ), consistent with the IHC data (Fig-
ure 1E ). This gene expression pattern demonstrated that the AR
variant in mouse prostate functions in a way closely mimicking that
in human cancer. Furthermore, our Pb-ARv567esmouse demonstrates
that the distinct AR variant transcriptome is a common and direct
molecular consequence when AR-Vs occur and further suggests that
activation of this transcriptome increases prostate epithelial cell pro-
gression by enhancing passage through the cell cycle.
To identify potential changes in RNA transcripts underlying
ARv567es-mediated tumorigenesis, we further examined the transcrip-
tional reprogramming of Tg mice prostates using mouse whole
genome expression oligonucleotide microarray analyses. Gene set
enrichment analysis (GSEA; Figure 5, A and B) showed differentially
regulated gene sets that included inflammatory-related cytokines,
transcriptional factors, and tumorigenesis-associated factors. We
further verified some genes in the upregulated oncology signatures
including Kras (Figure 5C ), nuclear factor kappa B (NF-κB) (Fig-
ure 5D), and β-catenin/Wnt pathway (Figure 5E ) related markers.
These data suggest that ARv567es induces a reprogramming of cellular
transcriptional activity and upregulates the expression of a spectrum
of genes that are critical for tumor initiation and progression.
Discussion
Two constitutively active AR-Vs have been described in clinical disease,
AR-V7 and ARv567es. AR-V7 is reported in most prostate tissues both
benign and malignant, but ARv567es has only been seen in malignant
prostate glands [12,20,22,23]. Although ARv567es is not the most fre-
quently expressed AR-V, we chose to use ARv567es in our Tg mouse
because this variant is the most restricted to prostate malignancy.
The most impressive finding in the present study was that
ARv567es could induce prostate cancer autonomously from de novo
as well as contribute to progression to CRPC following castration,
findings that have not been previously reported. These findings are
of great value in light of the current differing hypotheses concerning
the role of AR-Vs in prostate cancer, especially CRPC: one hypoth-
esis regards the occurrence of variants as a phenomenon, as only the
by-product of CRPC, whereas the other hypothesis attributes to AR-Vs
a role in CRPC, in which AR-Vs precipitate the progression and con-
tribute to the devastating outcome of CRPC. In our data, we showed
that ARv567es could induce cancer development de novo as well as
induce progression to CRPC.
A mitotic transcriptome has been associated with CRPC in human
studies [12,17,19,30]. Importantly, recent data showed the AR-Vs are
associated with a more mitotic transcriptome than AR-FL [22,29].
Consistent with these findings, our data also showed upregulated
mitotic genes including Ki67 and Ube2c. Ube2c is an anaphase-
promoting complex/cyclosome–specific E2 ubiquitin-conjugating
enzyme that has a critical role in anaphase-promoting complex/
cyclosome–dependent M-phase cell cycle progression by inactivating
the M-phase checkpoint. Ube2c has been shown to be a prominent
oncogene and is found overexpressed in various types of solid tumors
including late-stage prostate cancer [30,31]. In addition to in vitro
studies, these data from our Tg mouse further support that an AR-V–
activated mitotic transcriptome plays a critical role in CRPC.
In addition to the transcriptome shift to mitotic genes that aug-
ments proliferation and cell growth, panels of tumorigenesis-related
gene signatures were differentially regulated. In the Tg prostates,
significant up-regulation of five oncogenic signatures that have been
associated with prostate cancer initiation, progression, and metastasis
was detected by GSEA: K-RAS, NF-κB, STK33, Gli1, and β-catenin.
K-RAS has been associated with prostate cancer progression, specifi-
cally a role in EMT and metastatic progression [32]. Further, in cells
that are K-RAS dependent, STK33 promotes cancer cell viability
[33,34]. The inflammatory transcription factor NF-κB plays an early
role in cellular transformation as well as therapy resistance and meta-
static progression [35,36]. Overexpression of β-catenin contributes to
invasion of prostate cancer [37], whereas Gli1, which binds directly to
the AR, contributes to the development of CRPC [38]. Examination
of the cross talk of ARv567es with these oncologic pathways would be a
highly necessary task in future studies.
Given the evidence of the autonomous process of tumorigenesis
induced by ARv567es as well as its role in the development of CRPC,
this novel Tg mouse will be an excellent model for more in-depth
studies of the role of AR variant in prostate cancer development
and progression. Future studies crossing the Pb-ARv567es with current
CRPC mouse models would provide unique CRPC models in which
to examine the direct role of AR variant in CRPC development, pro-
gression, and therapy resistance.
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Figure W1. (A) Diagrammatic representation of the Tg construct. The human AR splice variant ARv567es coding sequence was subcloned
between AR2Pb promoter and the human growth hormone polyadenylation signal. Exon 8 (E8) is short and unique in spliced ARv567es
with a stop codon after the first 29 nucleotides, which results in a reading frame shift. (B) RT-PCR genotyping identified one Pb-ARv567es
founder (No. 187) with the expression of ARv567es from a panel of 10 founders. (C) Representative qPCR identifying homozygous and
heterozygous offspring in the positively genotyped Pb-ARv567es mice. Mouse Nos. 729, 733, 734, 736, 737, 744, 745, and 747 are het-
erozygous, and the others are homozygous.
Table W1. Weight Data of Body, GU Organs, and Prostate Expressed as Mean ± SD (g).
Body GU Prostate Relative GU Relative Prostate
Wt-sham (n = 6) 31.16 ± 1.32 0.46 ± 0.072 0.13 ± 0.016 0.0146 ± 0.0019 0.0041 ± 0.0005
Wt-castration (n = 8) 28.39 ± 0.88 0.11 ± 0.018 0.05 ± 0.008 0.0039 ± 0.0006 0.0018 ± 0.0003
Tg-sham (n = 7) 36.80 ± 3.23 0.64 ± 0.002 0.17 ± 0.023 0.0173 ± 0.0020 0.0047 ± 0.0005
Tg-castration (n = 7) 33.16 ± 2.82 0.22 ± 0.096 0.07 ± 0.013 0.0065 ± 0.0024 0.0022 ± 0.0004
Pb-ARv567es Tg mice and Wt littermates received castration or sham operation at the age of 16 weeks and were harvested 3 weeks post-surgery. Relative weight is GU or prostate weight normalized by
body weight.
Figure W2. Constitutive expression pattern of ARv567es in the mouse model Pb-ARv567es. (A) mRNA level of ARv567es showed lower but
no significant changes in Pb-ARv567es mice after castration. (B) The nuclear expression of ARv567es protein remained in castrated
Pb-ARv567es prostate. (C) IHC of endogenous mouse AR protein showed significant decrease after castration both in Pb-ARv567es
mice and Wt littermates.
Table W2. Pathology Distribution of Pb-ARv567es and Wt Prostate.
Age (Weeks) Pathology Intact Pb-ARv567es Castrated Pb-ARv567es Intact Wt Castrated Wt
16-20 Hyperplasia 7/7 (100%) 7/7 (100%) 0/6 0/6
30-40 Hyperplasia 2/5 (40%) N/A 1/6 (16.7%) N/A
PIN 3/5 (60%) N/A 0/6 N/A
50-60 Hyperplasia 0/6 0/6 2/6 (33.4%) 2/6 (33.4%)
High-grade PIN 2/6 (33.3%) 0/6 0/6 0/6
Adenocarcinoma 4/6 (66.7%) 6/6 (100%) 0/6 0/6
Localized 4/6 (66.7%) 4/6 (66.7%) 0/6 0/6
Invasive 0/6 2/6 (33.3%) 0/6 0/6
N/A, castration is not available in mice at 30 to 40 weeks of age.
Figure W3. (A) No antibody control for AR441 staining on Pb-ARv567es mice of 16 to 20 weeks of age. HRP–anti-mouse IgG secondary
antibody was used without adding AR441 antibody (×400). (B) Representative Ki-67 IHC pictures in young mice of 16 to 20 weeks of age
(×400). (C) Representative TUNEL pictures in young mice of 16 to 20 weeks of age (×400).
